Led by researchers at the Vanderbilt University Medical Center, a new study reports that Optellum's FDA-cleared Lung Cancer Prediction (LCP) AI assisted risk stratification for indeterminate lung ...
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient populations LOUISVILLE, Colo., March 20, 2026 ...
Histology-first classification (adenocarcinoma versus squamous) remains foundational, with molecular profiling driving first-line selection and determining eligibility for recently approved targeted ...
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. With lung cancer the ...
DEAR DR. ROACH: I am an 85-year-old woman who still drives, volunteers, attends club meetings, is a voracious reader, and doesn’t need help. I take metoprolol, losartan, hydralazine and furosemide. My ...
Abstract: Recent advances in deep learning (DL) have shown promising results in the identification of malignant lung nodules from computed tomography (CT) scans. However, conventional DL models ...
Lung adenocarcinoma (LUAD), the most common subtype of non-small cell lung cancer, is a form of malignant pulmonary nodule that requires clinical differentiation from benign pulmonary nodules (BPN).
Background Prospective validation and comparison of the performance of nodule management protocols is limited. The aim of this study was to examine the performance of size and risk thresholds for ...
Patients with stage 4 lung cancer and EGFR mutations may benefit from combination therapies that improve disease control. The American Society of Clinical Oncology (ASCO) released updated treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results